Company Description

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States.

Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.

The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.

Oragenics, Inc.

Country	United States
Founded	1996
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Janet Huffman

Contact Details

Address: 9015 Town Center Parkway, Suite 143 Lakewood Ranch, Florida 34202 United States
Phone	813 286 7900
Website	oragenics.com

Stock Details

Ticker Symbol	OGEN
Exchange	NYSEAMERICAN
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001174940
CUSIP Number	684023609
ISIN Number	US6840236094
Employer ID	59-3410522
SIC Code	2834

Key Executives

Name	Position
Janet Huffman	Chief Executive Officer, President, Chief Financial Officer, Secretary and Treasurer
Charles L. Pope CPA	Executive Chairman
Dr. James P. Kelly M.A., M.D.	Chief Medical Officer
Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D.	Chief Clinical Officer

Latest SEC Filings

Date	Type	Title
Mar 19, 2026	S-3/A	[Amend] Registration statement under Securities Act of 1933
Mar 16, 2026	10-K	Annual Report
Mar 11, 2026	8-K	Current Report
Jan 22, 2026	S-3	Registration statement under Securities Act of 1933
Jan 22, 2026	8-K	Current Report
Jan 21, 2026	SCHEDULE 13G	Filing
Jan 20, 2026	8-K	Current Report
Dec 15, 2025	8-K	Current Report
Dec 12, 2025	144	Filing
Nov 12, 2025	8-K	Current Report

View All SEC Filings